Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subanesthetic esketamine for perioperative neurocognitive disorders in metabolic syndrome patients undergoing major abdominal surgery
ChiCTR2500104082Phase 4Completed
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in perioperative neurocognitive disorder, post-operative cognitive decline (POCD) and postoperative delirium (POD) (2 arms), sponsored by Yantai Yuhuangding Hospital. Primary endpoints: Incidence of delayed neurocognitive recovery, Mini-Mental State Examination score and 1 more. Started Jun 2025; status: completed.
02
Drugs
esketamine
03
Conditions
perioperative neurocognitive disorderpost-operative cognitive decline (POCD)postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2500104082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104082.